280 related articles for article (PubMed ID: 16162081)
21. Randomized, double-blind, 3-month parallel study of the effects of pramipexole, pergolide, and placebo on Parkinsonian tremor.
Navan P; Findley LJ; Jeffs JA; Pearce RK; Bain PG
Mov Disord; 2003 Nov; 18(11):1324-31. PubMed ID: 14639675
[TBL] [Abstract][Full Text] [Related]
22. DA agonists -- non-ergot derivatives: pramipexole: management of Parkinson's disease.
Mov Disord; 2002; 17 Suppl 4():S93-7. PubMed ID: 12211148
[No Abstract] [Full Text] [Related]
23. Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease.
Mizuno Y; Yanagisawa N; Kuno S; Yamamoto M; Hasegawa K; Origasa H; Kowa H;
Mov Disord; 2003 Oct; 18(10):1149-56. PubMed ID: 14534919
[TBL] [Abstract][Full Text] [Related]
24. Pramipexole for the treatment of early Parkinson's disease.
Perez-Lloret S; Rey MV; Ratti L; Rascol O
Expert Rev Neurother; 2011 Jul; 11(7):925-35. PubMed ID: 21721909
[TBL] [Abstract][Full Text] [Related]
25. Pramipexole--a new dopamine agonist for the treatment of Parkinson's disease.
Bennett JP; Piercey MF
J Neurol Sci; 1999 Feb; 163(1):25-31. PubMed ID: 10223406
[TBL] [Abstract][Full Text] [Related]
26. Anhedonia, depression, and motor functioning in Parkinson's disease during treatment with pramipexole.
Lemke MR; Brecht HM; Koester J; Kraus PH; Reichmann H
J Neuropsychiatry Clin Neurosci; 2005; 17(2):214-20. PubMed ID: 15939976
[TBL] [Abstract][Full Text] [Related]
27. Pramipexole and levodopa in early Parkinson's disease: dynamic changes in cost effectiveness.
Noyes K; Dick AW; Holloway RG;
Pharmacoeconomics; 2005; 23(12):1257-70. PubMed ID: 16336019
[TBL] [Abstract][Full Text] [Related]
28. Identifying poor symptom control in Parkinson's disease.
Scott L
Nurs Times; 2006 Mar 21-27; 102(12):30-2. PubMed ID: 16594560
[TBL] [Abstract][Full Text] [Related]
29. A randomly assigned double-blind cross-over study examining the relative anti-parkinsonian tremor effects of pramipexole and pergolide.
Navan P; Findley LJ; Undy MB; Pearce RK; Bain PG
Eur J Neurol; 2005 Jan; 12(1):1-8. PubMed ID: 15613140
[TBL] [Abstract][Full Text] [Related]
30. New dopamine agonist pramipexole improves parkinsonism and depression in Parkinson's disease.
Harada T; Ishizaki F; Horie N; Nitta Y; Yamada T; Sasaki T; Nagakane T; Yasumatsu Y; Nitta K; Katsuoka H
Hiroshima J Med Sci; 2011 Dec; 60(4):79-82. PubMed ID: 22389951
[TBL] [Abstract][Full Text] [Related]
31. Increase in body weight after pramipexole treatment in Parkinson's disease.
Kumru H; Santamaria J; Valldeoriola F; Marti MJ; Tolosa E
Mov Disord; 2006 Nov; 21(11):1972-4. PubMed ID: 16972276
[TBL] [Abstract][Full Text] [Related]
32. Pramipexole extended release in Parkinson's disease.
Hametner EM; Seppi K; Poewe W
Expert Rev Neurother; 2011 Sep; 11(9):1229-34. PubMed ID: 21864066
[TBL] [Abstract][Full Text] [Related]
33. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies.
Leentjens AF; Koester J; Fruh B; Shephard DT; Barone P; Houben JJ
Clin Ther; 2009 Jan; 31(1):89-98. PubMed ID: 19243709
[TBL] [Abstract][Full Text] [Related]
34. Modern therapy of Parkinson's disease.
Ransmayr G; Künig G; Gerstenbrand F
J Neural Transm Suppl; 1992; 38():129-40. PubMed ID: 1491245
[TBL] [Abstract][Full Text] [Related]
35. Dopamine agonist-based strategies in the treatment of Parkinson's disease.
Antonini A; Barone P
Neurol Sci; 2008 Dec; 29 Suppl 5():S371-4. PubMed ID: 19381765
[TBL] [Abstract][Full Text] [Related]
36. Pramipexole for Parkinson's disease.
Ting RM; Force RW
J Fam Pract; 1998 Jan; 46(1):19-20. PubMed ID: 9451363
[No Abstract] [Full Text] [Related]
37. A dopamine agonist, pramipexole, and cognitive functions in Parkinson's disease.
Relja M; Klepac N
J Neurol Sci; 2006 Oct; 248(1-2):251-4. PubMed ID: 16797593
[TBL] [Abstract][Full Text] [Related]
38. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD Study. Parkinson Study Group.
Clin Neuropharmacol; 2000; 23(1):34-44. PubMed ID: 10682229
[TBL] [Abstract][Full Text] [Related]
39. Pramipexole versus levodopa in patients with early Parkinson's disease: effect on generic and disease-specific quality of life.
Noyes K; Dick AW; Holloway RG;
Value Health; 2006; 9(1):28-38. PubMed ID: 16441522
[TBL] [Abstract][Full Text] [Related]
40. Telogen effluvium associated with the dopamine agonist pramipexole in a 55-year-old woman with Parkinson's disease.
Katz KA; Cotsarelis G; Gupta R; Seykora JT
J Am Acad Dermatol; 2006 Nov; 55(5 Suppl):S103-4. PubMed ID: 17052518
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
